Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 32.07 USD -1.75% Market Closed
Market Cap: 680.5m USD

Wall Street
Price Targets

LYEL Price Targets Summary
Lyell Immunopharma Inc

Wall Street analysts forecast LYEL stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYEL is 19.38 USD with a low forecast of 12.12 USD and a high forecast of 26.25 USD.

Lowest
Price Target
12.12 USD
62% Downside
Average
Price Target
19.38 USD
40% Downside
Highest
Price Target
26.25 USD
18% Downside
Lyell Immunopharma Inc Competitors:
Price Targets
1801
Innovent Biologics Inc
33% Upside
BVXP
Bioventix PLC
134% Upside
FYB
Formycon AG
111% Upside
ACLX
Arcellx Inc
76% Upside
INSM
Insmed Inc
10% Upside
MRNA
Moderna Inc
25% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
36% Upside
VNDA
Vanda Pharmaceuticals Inc
76% Upside

Revenue
Forecast

Revenue Estimate
Lyell Immunopharma Inc

For the last 4 years the compound annual growth rate for Lyell Immunopharma Inc's revenue is -70%. The projected CAGR for the next 4 years is 423%.

-70%
Past Growth
423%
Estimated Growth
Estimates Accuracy
62%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Lyell Immunopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Lyell Immunopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYEL's stock price target?
Price Target
19.38 USD

According to Wall Street analysts, the average 1-year price target for LYEL is 19.38 USD with a low forecast of 12.12 USD and a high forecast of 26.25 USD.

What is Lyell Immunopharma Inc's Revenue forecast?
Projected CAGR
423%

For the last 4 years the compound annual growth rate for Lyell Immunopharma Inc's revenue is -70%. The projected CAGR for the next 4 years is 423%.

Back to Top